Mutation Spectrum of EGFR From 21,324 Chinese Patients With Non-Small Cell Lung Cancer (NSCLC) Successfully Tested by Multiple Methods in a CAP-Accredited Laboratory
| Autor: | Xiaoyong Ou, Hu Changming, Xiangdong Ding, Mao Linlin, Changhong Zhou, Xiaoxia Li, Pifu Luo, Yu Shihui, Weiwei Zhao, Xu Yanyan, Shangfei Zhang, Zhou Danyan, Tang Yuanxiao, Ou Xiaohua |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Male
0301 basic medicine Oncology Sanger sequencing Cancer Research Lung Neoplasms non-small cell lung cancer (NSCLC) medicine.disease_cause 0302 clinical medicine Carcinoma Non-Small-Cell Lung Epidermal growth factor receptor Original Research Aged 80 and over Mutation biology High-Throughput Nucleotide Sequencing General Medicine Middle Aged Prognosis ErbB Receptors Society Journal Archive Real-time polymerase chain reaction 030220 oncology & carcinogenesis symbols Female Adult China medicine.medical_specialty DNA sequencing Pathology and Forensic Medicine Young Adult 03 medical and health sciences symbols.namesake Asian People Internal medicine Biomarkers Tumor medicine Humans Gene Genotyping non-small cell lung cancer Aged Retrospective Studies EGFR mutation testing business.industry medicine.disease 030104 developmental biology biology.protein next-generation sequencing real-time PCR Laboratories business Follow-Up Studies |
| Zdroj: | Pathology and Oncology Research |
| ISSN: | 1532-2807 |
| DOI: | 10.3389/pore.2021.602726 |
| Popis: | Genotyping epidermal growth factor receptor (EGFR) gene in patients with advanced non-small cell lung cancers (NSCLC) is essential for identifying those patients who may benefit from targeted therapies. Systemically evaluating EGFR mutation detection rates of different methods currently used in clinical setting will provide valuable information to clinicians and laboratory scientists who take care of NSCLC patients. This study retrospectively reviewed the EGFR data obtained in our laboratory in last 10 years. A total of 21,324 NSCLC cases successfully underwent EGFR genotyping for clinical therapeutic purpose, including 5,244 cases tested by Sanger sequencing, 13,329 cases tested by real-time PCR, and 2,751 tested by next-generation sequencing (NGS). The average EGFR mutation rate was 45.1%, with 40.3% identified by Sanger sequencing, 46.5% by real-time PCR and 47.5% by NGS. Of these cases with EGFR mutations identified, 93.3% of them harbored a single EGFR mutation (92.1% with 19del or L858R, and 7.9% with uncommon mutations) and 6.7% harbored complex EGFR mutations. Of the 72 distinct EGFR variants identified in this study, 15 of them (single or complex EGFR mutations) were newly identified in NSCLC. For these cases with EGFR mutations tested by NGS, 65.3% of them also carried tumor-related variants in some non-EGFR genes and about one third of them were considered candidates of targeted drugs. NGS method showed advantages over Sanger sequencing and real-time PCR not only by providing the highest mutation detection rate of EGFR but also by identifying actionable non-EGFR mutations with targeted drugs in clinical setting. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|